| 石织宏,黄织春.曲妥珠单抗联合IP方案或SOX方案化疗在人类表皮生长因子受体-2阳性晚期胃癌中的有效性和安全性比较[J].安徽医药,2019,23(2):368-371. |
| 曲妥珠单抗联合IP方案或SOX方案化疗在人类表皮生长因子受体-2阳性晚期胃癌中的有效性和安全性比较 |
| Comparison of the efficacy and safety between IP regimenand SOX regimen chemotherapy combined with Trastuzumab in HER-2 positive advanced gastric cancer patients |
| 投稿时间：2017-08-14 |
| DOI： |
| 中文关键词: 曲妥珠单抗 伊立替康+顺铂(IP方案) 替吉奥+奥沙利铂(SOX方案) 人类表皮生长因子受体-2 晚期胃癌 |
| 英文关键词: Trastuzumab SOX regimen IP regimen HER-2 Advanced gastric |
| 基金项目: |
|
| 摘要点击次数: 1998 |
| 全文下载次数: 570 |
| 中文摘要: |
| 目的 探讨人类表皮生长因子受体-2(HER-2)阳性晚期胃癌中曲妥珠单抗联合IP方案或SOX方案化疗的有效性和安全性。方法 连续性纳入自2015年6月至2017年6月内蒙古医科大学附属医院收治的58例HER-2阳性晚期胃癌,利用随机数字表法分为SOX组和IP组,每组29例。SOX组给予曲妥珠单抗联合替吉奥+奥沙利铂治疗；IP组给予曲妥珠单抗联合伊立替康+顺铂治疗,比较两个疗程后两组病人血清肿瘤标志物和新生血管标志物的变化,以及化疗效果和不良反应差异。结果 两个治疗疗程后,两组病人血清肿瘤标志物癌胚抗原(CEA),糖类蛋白19-9(CA19-9),糖类抗原125(CA125)以及组织多肽特异性抗原(TPS)水平均差异无统计学意义(t=0.628,P=0.532；t=0.879,P=0.383；t=0.828,P=0.411；t=0.719,P=0.476)；新生血管标志物内皮生长因子(VEGF)、血管生成素-2(Ang-2)、内皮抑素(ES)、色素上皮衍生因子(PEDF)水平亦差异无统计学意义(t=0.701,P=0.486；t=0.955,P=0.343；t=1.803,P=0.077；t=0.991,P=0.326；)；SOX组客观有效率(ORR)及病控制率(DCR)分别为44.83%和82.76%；IP组ORR及DCR分别为34.48%和69.97%,均差异无统计学意义(χ2=0.648,P=0.421；χ2=1.506,P=0.219)。但IP组骨髓抑制(58.62%)和恶心呕吐(3.45%)发生率明显高于SOX组(31.03%,6.90%),差异有统计学意义(χ2=4.461,P=0.035；χ2=5.836,P=0.016)。结论 曲妥珠单抗联合SOX化疗方案或IP方案在HER-2阳性晚期胃癌病人中疗效相当,但SOX方案不良反应发生率较少,值得临床推广。 |
| 英文摘要: |
| Objective To investigate the differences in efficacy and safety between IP regimen and SOX regimen chemotherapy combined with Trastuzumab in HER-2 positive advanced gastric cancer patients.Methods A total of 58 patients with HER-2 positive advanced gastric cancer were admitted to The Affiliated Hospital of Inner Mongolia Medical University from June 2015 to June 2017,and they were randomly assigned into 2 groups using random number table:SOX group and IP group,each with 29 cases.The SOX group was given Trastuzumab combined with the treatment of Oteracil potassium + Oxaliplatin,while the IP group was given Trastuzumab combined Irinotecan + Cisplatin therapy.Serum tumor markers,new blood vessel markers,curative effect of chemotherapy and adverse reactions were compared between the two groups after two treatment courses.Results After 2 courses of treatment,no statistical differences were found in serum tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9),carbohydrate antigen 125 (CA125),as well as the level of tissue polypeptide specific antigen (TPS) (t=0.628,P=0.532;t=0.879,P=0.383;t=0.828,P=0.411;t=0.719,P=0.476);no statistical differences were found in vascular endothelial growth factor (VEGF),angiopoietin-2 (Ang-2),endostatin (ES),and pigment epithelium derived factor (PEDF) (t=0.701,P=0.486;t=0.955,P=0.343;t=1.803,P=0.077;t=0.991,P=0.326).The objective response rate (ORR) and disease control rate (DCR) of SOX group were 44.83% and 82.76%,respectively and the ORR and DCR of IP group were 34.48% and 69.97%,respectively,with no statistical difference (χ2=0.648,P=0.421;χ2=1.506,P=0.219).However,the incidences of bone marrow suppression (58.62%) and nausea vomiting (58.62%) in IP group were significantly higher than those in the SOX group (χ2=4.461,P=0.035;χ2=5.836,P=0.016).Conclusions The clinical efficacies of Trastuzumab combined with SOX or IP chemotherapy regimen were comparable in patients with HER-2 positive advanced gastric cancer,but the incidence of adverse reactions in SOX scheme was lower,which was worthy of clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
